CTLA4 and cancer: Several ICIs against PD-1, PD-L1, CTLA-4, and LAG3 are FDA-approved therapies for several different types of cancers including melanoma, lung, gastrointestinal, breast, and renal cell cancer (Vaddepally et al., 2020).